The FDA-approved GLP-1 receptor agonists are exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and efpeglenatide (Eperzan)
If you're considering a larger supply, it makes sense to review the label on a smaller initial order before scaling up
These effects are generally mild to moderate in severity and tend to diminish over time as the body adapts to the medication
The established urinary threshold level of 150 g/mL may be reached (rarely, but possibly) in some individuals within 6-20 hours of taking some long-acting therapeutic formulations
Fluid retention, dose titration phases, metabolic adaptation, dietary habits, and underlying health conditions can all contribute to unexpected weight changes during treatment